The size of the Zika Virus Vaccines Market in Europe was worth USD 4.19 billion in 2020. It is estimated to be growing at a CAGR of 4.32% to reach USD 5.17 billion by 2025.
Zika virus is a mosquito-borne fever caused by Aedes mosquitoes when they are active in the day-time. It is similar to yellow fever, West Nile virus, and dengue. Zika vaccines are developed to prevent and control diseases caused by the zika virus. This disease has no symptoms or sometimes very mild symptoms like a minimal form of dengue fever, skin rash, and joint pains. It is transmitted sexually from the infected person or the infected pregnant woman to the baby.
Government initiatives, a large population of the patients, an increase in healthcare expenditure, and disposable income drive the vaccine market. Reimbursement, favorable government policies, close attention towards pregnant women, a rise in incidences in the Zika virus, and advanced technology developments in health care are driving the European Zika virus vaccine market. An increase in understanding of Zika virus infection and investments made by the private companies causes the European Zika virus vaccine market.
World Health Organization (WHO) has announced that the Zika virus is less widespread in some areas or communities, etc., which are the factors that are restraining the local market. The requirement of an enormous amount of money investments in the development of vaccines may also control the market's growth. Lack of awareness is also projected to hinder the expansion of the European Zika virus vaccine market.
The opportunities in the European Zika virus vaccines market include the need to prevent the virus, immunization of vaccines, treatment for Zika linked congenital disabilities, i.e., newborn babies diagnosed with the link of the Zika virus and other supporting factors within the area. The factors mentioned in the challenges have resulted in the interest of the pharmaceutical organizations to invest and capitalize on the growth challenges.
The crucial challenges that come in face to face with the healthcare and government in the regions like Europe are the continuous spreading of the Zika virus and the deficiency of preventive and effective medical solutions towards the treatment. To overcome these challenges, the government and other research institutes are motivating and supporting the pharmaceutical regions to invest, fund, and allot infrastructure and outsourcing of labor. The in-depth analysis provides insight into the growth and challenges involved in the European Zika virus vaccines Market.
This report on European Zika Vaccines Market has been segmented & sub-segmented into the following categories:
Regionally, In Europe, Germany leads the zika virus vaccine market, followed by France and U.K. The market in this region is projected to grow strongly during the forecast period due to various factors such as growing awareness and favorable reimbursement policies.
The opportunities for the European Zika virus vaccines market include the need to prevent the virus, immunization of vaccines, treatment for Zika linked congenital disabilities, i.e., newborn babies diagnosed with links of the Zika virus and other supporting factors within the area. The factors mentioned in the challenges have resulted in the pharmaceutical organizations' interest in investing and capitalizing on the growth challenges.
The challenges the healthcare institutes and government face in Europe are the constant spread of the Zika virus and the lack of preventive and effective medical solutions. The government and several research institutes support and invest, fund, and allot infrastructure and labor outsourcing in the pharmaceutical regions.
Germany leads the Zika virus vaccine market, followed by France and U.K. The market is expected to grow strongly during the forecast period in Europe due to various factors such as increasing awareness and healthy compensation plans.
Prominent companies in the Europe Zika virus vaccines market profiled in this report are Takeda Pharmaceutical Co. Ltd., NewLink Genetics Co., Immunovaccine Inc., GeneOne Life Science Inc., GlaxoSmithKline PLC, Inovio Pharmaceuticals, Inc., Bharat Biotech International Ltd., Hawaii Biotech Inc., and Sanofi S.A.
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3.1 Executive Summary
3.2 Key Inferences
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1.2 Therapeutic Vaccines
5.1.3 Preventive Vaccines
5.1.4 Y-o-Y Growth Analysis, By Type
5.1.5 Market Attractiveness Analysis, By Type
5.1.6 Market Share Analysis, By Type
5.2.4 Research institutes
5.2.6 Y-o-Y Growth Analysis, By End-user
5.2.7 Market Attractiveness Analysis, By End-user
5.2.8 Market Share Analysis, By End-user
6. Geographical Analysis
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Type
184.108.40.206 By End-user
6.1.4 Market Attractiveness Analysis
220.127.116.11 By Geographical Area
18.104.22.168 By Type
22.214.171.124 By End-user
6.1.5 Market Share Analysis
126.96.36.199 By Geographical Area
188.8.131.52 By Type
184.108.40.206 By End-user
7. Strategic Analysis
7.1 PESTLE analysis
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Takeda Pharmaceutical Co. Ltd.,
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 NewLink Genetics Co.,
8.3 Immunovaccine Inc.,
8.4 GeneOne Life Science Inc.,
8.5 GlaxoSmithKline plc.,
8.6 ., Inovio Pharmaceuticals, Inc.,
8.7 Bharat Biotech International Ltd.,
8.8 Hawaii Biotech Inc.,
8.9 Sanofi S.A.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
a) List of Tables
b) List of Figures